Skip to main content

Table 1 Serum liver function tests, lipid and apolipoprotein levels in control subjects and patients with liver cirrhosis.

From: Decreased paraoxonase-1 activity is associated with alterations of high-density lipoprotein particles in chronic liver impairment

Variable Control subjects Patients p
Albumin; g/L 41.5 (1.6) 36.6 (9.1) 0.005
Alanine aminotransferase; μkat/L 0.31 (0.08) 1.08 (0.70) 0.041
Aspartate aminotransferase; μkat/L 0.35 (0.06) 1.57 (0.99) 0.025
γ-glutamyl transferase; μkat/L 0.39 (0.27) 1.19 (1.06) 0.141
Alkaline phosphatase; μkat/L 0.79 (0.25) 5.81 (4.11) 0.026
Bilirubin; μmol/L 12.8 (1.9) 19.4 (16.1) 0.410
Total peroxides: μmol/L 93.2 (12.2) 338.8 (133.2) 0.003
Monocyte chemoattractant protein-1; ng/L 41.1 (3.4) 146.0 (54.9) 0.003
Type III procollagen-N-peptide; μg/L 2.2 (1.3) 10.2 (3.3) 0.001
Paraoxonase-1 activity; U/L 362.9 (36.6) 94.9 (11.0) < 0.001
Paraoxonase-1 concentration; mg/L 62.1 (25.5) 189.3 (48.3) 0.002
Cholesterol; mmol/L 5.26 (1.29) 4.24 (2.00) 0.366
Free cholesterol; mmol/L 1.37 (0.36) 1.48 (0.76) 0.795
Triglycerides; mmol/L 1.26 (0.19) 1.31 (0.54) 0.843
Phospholipids; mmol/L 1.38 (0.36) 1.48 (0.76) 0.795
HDL-cholesterol; mmol/L 1.80 (0.50) 1.19 (0.27) 0.044
Apolipoprotein A-I; g/L 1.41 (0.40) 0.89 (0.27) 0.050
Apolipoprotein A-II; g/L 0.31 (0.11) 0.22 (0.11) 0.234
Apolipoprotein E; mg/L 25.59 (5.37) 39.20 (24.62) 0.262
  1. Values are expressed as means and SD (in parenthesis).